Pasar al contenido principal

ESTUDIO GENETICO Y EPIGENETICO DEL TRATAMIENTO HORMONAL CRUZADO EN UNA POBLACION TRANSEXUAL: UN ESTUDIO LONGITUDINAL

PGC2018-094919-B-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento Científico y Tecnológico del Sistema de I+D+i
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DA CORUÑA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Analysis of Four Polymorphisms Located at the Promoter of the Estrogen Receptor Alpha ESR1 Gene in a Population With Gender Incongruence

  • Fernández, Rosa
  • Delgado Zayas, Enrique
  • Ramirez Olivero, Karla del Valle
  • Cortés-Cortés, Joselyn
  • Gómez-Gil, Esther
  • Esteva de Antonio, Isabel
  • Almaraz, María Cruz
  • Guillamon, Antonio
  • Pásaro, Eduardo
[Abstract] Introduction: Gender incongruence defines a state in which individuals feel discrepancy between the sex assigned at birth and their gender. Some of these people make a social transition from male to female (transwomen) or from female to male (trans men). By contrast, the word cisgender describes a person whose gender identity is consistent with their sex assigned at birth. Aim: To analyze the implication of the estrogen receptor a gene (ESR1) in the genetic basis of gender incongruence. Main Outcome Measures: Polymorphisms rs9478245, rs3138774, rs2234693, rs9340799. Method: We carried out the analysis of 4 polymorphisms located at the promoter of the ESR1 gene (C1 ¼ rs9478245, C2 ¼ rs3138774, C3 ¼ rs2234693, and C4 ¼ rs9340799) in a population of 273 trans women, 226 trans men, and 537 cis gender controls. For SNP polymorphisms, the allele and genotype frequencies were analyzed by c2 test. The strength of the SNP associations with gender incongruence was measured by binary logistic regression. For the STR polymorphism, the mean number of repeats were analyzed by the ManneWhitney U test. Measurement of linkage disequilibrium and haplotype frequencies were also performed. Results: The C2 median repeats were shorter in the trans men population. Genotypes S/S and S/L for the C2 polymorphism were overrepresented in the trans men group (P ¼ .012 and P ¼ .003 respectively). We also found overtransmission of the A/A genotype (C4) in the trans men population (P ¼ .017), while the A/G genotype (C4) was subrepresented (P ¼ .009]. The analyzed polymorphisms were in linkage disequilibrium. In the trans men population, the T(C1)-L(C2)-C(C3)-A(C4) haplotype was overrepresented (P ¼ .019) while the T(C1)-L(C2)-C(C3)-G(C4) was subrepresented (P ¼ .005). Conclusion: The ESR1 is associated with gender incongruence in the trans men population, This work was supported by grants: ED431B 019/02 (EP), PGC2018-094919-B-C21 (AG), PGC2018-094919-B-C22 (RF), and FPU 15/02558 (JCC), Xunta de Galicia; ED431B 019/02
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Gender-Affirming Hormone Therapy Modifies the CpG Methylation Pattern of the ESR1 Gene Promoter After Six Months of Treatment in Transmen

  • Fernández, Rosa
  • Ramirez Olivero, Karla del Valle
  • Gómez-Gil, Esther
  • Cortés-Cortés, Joselyn
  • Mora, Mireia
  • Aranda, Gloria
  • Delgado Zayas, Enrique
  • Esteva de Antonio, Isabel
  • Almaraz, María Cruz
  • Guillamon, Antonio
  • Pásaro, Eduardo
[Abstract] Background Brain sexual differentiation is a process that results from the effects of sex steroids on the developing brain. Evidence shows that epigenetics plays a main role in the formation of enduring brain sex differences and that the estrogen receptor α (ESR1) is one of the implicated genes. Aim To analyze whether the methylation of region III (RIII) of the ESR1 promoter is involved in the biological basis of gender dysphoria. Methods We carried out a prospective study of the CpG methylation profile of RIII (−1,188 to −790 bp) of the ESR1 promoter using bisulfite genomic sequencing in a cisgender population (10 men and 10 women) and in a transgender population (10 trans men and 10 trans women), before and after 6 months of gender-affirming hormone treatment. Cisgender and transgender populations were matched by geographical origin, age, and sex. DNAs were treated with bisulfite, amplified, cloned, and sequenced. At least 10 clones per individual from independent polymerase chain reactions were sequenced. The analysis of 671 bisulfite sequences was carried out with the QUMA (QUantification tool for Methylation Analysis) program. Outcomes The main outcome of this study was RIII analysis using bisulfite genomic sequencing. Results We found sex differences in RIII methylation profiles in cisgender and transgender populations. Cismen showed a higher methylation degree than ciswomen at CpG sites 297, 306, 509, and at the total fragment (P ≤ .003, P ≤ .026, P ≤ .001, P ≤ .006). Transmen showed a lower methylation level than trans women at sites 306, 372, and at the total fragment (P ≤ .0001, P ≤ .018, P ≤ .0107). Before the hormone treatment, transmen showed the lowest methylation level with respect to cisgender and transgender populations, whereas transwomen reached an intermediate methylation level between both the cisgender groups. After the hormone treatment, transmen showed a statistically significant methylation increase, whereas transwomen showed a non-significant methylation decrease. After the hormone treatment, the RIII methylation differences between transmen and transwomen disappeared, and both transgender groups reached an intermediate methylation level between both the cisgender groups. Clinical Implications Clinical implications in the hormonal treatment of trans people. Strengths & Limitations Increasing the number of regions analyzed in the ESR1 promoter and increasing the number of tissues analyzed would provide a better understanding of the variation in the methylation pattern. Conclusions Our data showed sex differences in RIII methylation patterns in cisgender and transgender populations before the hormone treatment. Furthermore, before the hormone treatment, transwomen and transmen showed a characteristic methylation profile, different from both the cisgender groups. But the hormonal treatment modified RIII methylation in trans populations, which are now more similar to their gender. Therefore, our results suggest that the methylation of RIII could be involved in gender dysphoria., This work was supported by grants: Xunta de Galicia ED431 B 019/02 (EP), PGC2018-094919-B-C21 (AG), Ministerio de ciencia, innovación y Universidades PGC2018-094919-B-C22 (RF, EP). J. Cortés-Cortés was supported by a doctoral fellowship FPU 15/02558, Xunta de Galicia ED431 B 019/02
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Editorial: Research in Transgender Healthcare: What Have We Learned and Where Are We Going?

  • Fernández, Rosa
  • Burke, Sarah M.
This article was submitted to Neuroendocrine Science, a section of the journal Frontiers in Endocrinology, This article is part of the research topic: Research in Transgender Healthcare: What Have We Learned and Where are We Going?, [Abstract] Gender incongruence (GI) is defined as “an individual’s discontent with their assigned gender and their identification with a gender other than that associated with their birth sex based on physical sex characteristics”. The origin of GI appears to be complex and multifactorial. From the extensive research that has been conducted over the past few years, three main factors have been identified as key mechanisms for understanding GI: genes, hormones, and the environment. Accordingly, our Frontiers Research Topic includes twelve articles that cover very varied topics about GI, including cardiovascular effects of treatment, surgical outcomes, new treatment options and healthcare quality in a broader sense. This research involved the hard work of sixty-six authors that was carried out mainly in Europe (Austria, Belgium, Germany, Italy, Serbia, and Spain), Australia, and also the United States., This study was supported by the Spanish Ministry of Science and Innovation Grant No. PGC2018-094919-B-C22